Key result
Renal response after cardiac resynchronization therapy independently decreased the hazard of death, heart transplant, or LVAD (HR 0.24; 95% CI 0.08-0.73; P=0.01).
Why the study?
Does renal response following cardiac resynchronization therapy improve the composite outcome of death, heart transplant, and LVAD in patients with chronic kidney disease?
Cohort (n=260)
No
Does renal response following cardiac resynchronization therapy improve the composite outcome of death, heart transplant, and LVAD in patients with chronic kidney disease?
Hazard Ratio: 0.24 (95% CI 0.08–0.73)
p-value: p=0.01
In patients with heart failure and chronic kidney disease undergoing CRT, an improvement in renal function is a strong independent predictor of improved 5-year survival free from heart transplant or LVAD.
Renal response may refine post-CRT prognosis; hypothesis-generating and should not yet change practice.
BACKGROUND: Chronic kidney disease (CKD) severity is associated with increased morbidity and mortality in congestive heart failure. There is a paucity of data regarding renal improvement after cardiac resynchronization therapy (CRT) and its potential impact on clinical outcomes, especially in patients with severe CKD. METHOD: This was a retrospective analysis of a prospectively collected cohort of 260 patients with CKD undergoing CRT at a single center. Renal function was compared before and after CRT. The primary end point was a composite of death, heart transplant, and left ventricular assist device (LVAD), assessed at 5 years. RESULTS: Patients with more severe CKD demonstrated increased risk of death, transplant, or LVAD following CRT (P = 0.015). Renal response (estimated glomerular filtration rate improvement ≥10 mL/min/1.73 m(2) ) was observed in 14% of all patients and 28% of patients with stage IV CKD. Independent predictors of renal response included left ventricular ejection fraction improvement (odds ratio [OR] 1.06, confidence interval [CI] 1.01-1.10), angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use (OR 4.31, CI 1.08-17.23), and advanced CKD stage (OR 2.19, CI 1.14-4.23). Renal response independently decreased hazard of the primary outcome (HR 0.24, CI 0.08-0.73, P = 0.01). Renal responders with stage IV CKD had 80% 5-year event-free survival, compared to 0% for nonrenal responders in stage IV (P = 0.03). CONCLUSION: Although severity of CKD is associated with poorer outcome after CRT, improvement in renal function can occur in patients across all CKD stages. Renal responders, including those with stage IV CKD, demonstrate favorable 5-year outcomes. Assessment of renal response may help better prognostic outcomes following CRT.
No takes yet. Share an insight, caveat, or question.
Singal et al. (2015) conducted a cohort in Chronic kidney disease and congestive heart failure (n=260). Renal response (eGFR improvement ≥10 mL/min/1.73 m2) vs. No renal response was evaluated on Composite of death, heart transplant, and left ventricular assist device (LVAD) (HR 0.24, 95% CI 0.08-0.73, p=0.01). Renal response after cardiac resynchronization therapy independently decreased the hazard of death, heart transplant, or LVAD (HR 0.24; 95% CI 0.08-0.73; P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: